25/09/2026
🚨 “THROMBOTIC THROMBOCYTOPENIC PURPURA: THE MICROVASCULAR EMERGENCY THAT DEMANDS IMMEDIATE ACTION” 🩸🧬🩺
✅️Clinical Update (Responding to the CLINICAL CASE) 🧩
Hello friends of Pasión Médica Pro… A previously independent 27-year-old woman presents with 10 days of progressive violaceous lesions on both lower limbs. What began as pinpoint petechiae has become more extensive purpura, accompanied by profound fatigue, intermittent headache, difficulty concentrating, and dark urine.
During evaluation, she has pallor, mild tachycardia, severe thrombocytopenia, recent-onset anemia, elevated LDH and indirect bilirubin, moderate renal dysfunction, and schistocytes on the peripheral blood smear. Her coagulation profile is not altered in proportion to the severity of the thrombocytopenia. During observation, she develops transient disorientation without persistent focal neurologic deficit.
The diagnostic pattern is highly concerning for immune thrombotic thrombocytopenic purpura (iTTP) : microangiopathic hemolytic anemia, thrombocytopenia, neurologic symptoms, and organ ischemia caused by severe ADAMTS13 deficiency.
This is a hematologic emergency. Plasma exchange and corticosteroids must begin immediately after collecting blood for ADAMTS13 testing; treatment should not wait for the laboratory confirmation when clinical suspicion is high.
✅️ BACKGROUND AND CONCEPTUAL EVOLUTION 🩸📚
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by severe thrombocytopenia and microangiopathic hemolytic anemia due to platelet-rich microthrombi in the small vessels.
The modern understanding of TTP changed after the identification of ADAMTS13, a metalloprotease responsible for cleaving ultra-large von Willebrand factor multimers. In immune TTP, autoantibodies inhibit ADAMTS13 or accelerate its clearance.
Current international guidance recognizes two major forms:
🔹 Immune TTP (iTTP): acquired autoimmune disease, responsible for most adult cases.
🔹 Congenital TTP (cTTP or Upshaw–Schulman syndrome): inherited severe ADAMTS13 deficiency, usually caused by biallelic pathogenic variants.
TTP may affect the brain, heart, kidneys, gastrointestinal tract, and peripheral circulation. The historical “classic pentad” is not required for diagnosis, and waiting for all five manifestations can dangerously delay life-saving treatment.
✅️ UPDATED PATHOPHYSIOLOGY 🧬🔬
ADAMTS13 normally cleaves large von Willebrand factor multimers released by endothelial cells.
In immune TTP:
🔹 Autoantibodies cause severe ADAMTS13 deficiency, generally activity below 10%.
🔹 Ultra-large von Willebrand factor multimers remain in circulation and bind platelets excessively.
🔹 Platelet-rich microthrombi form within arterioles and capillaries.
🔹 Passing erythrocytes are mechanically fragmented, producing schistocytes and intravascular hemolysis.
🔹 Platelet consumption causes profound thrombocytopenia and mucocutaneous bleeding manifestations.
🔹 Microvascular ischemia may produce headache, confusion, seizures, myocardial injury, abdominal pain, or renal dysfunction.
Caplacizumab blocks the interaction between von Willebrand factor and platelets, while plasma exchange removes pathogenic autoantibodies and replenishes functional ADAMTS13. Corticosteroids and rituximab target the autoimmune process.
✅️ DEEP AND UPDATED CLINICAL FEATURES 😣
The presentation may be abrupt or evolve over days. Purpura is an important clue, but it does not reflect a purely bleeding disorder.
⭕️ Petechiae, purpura, ecchymoses, epistaxis, or gingival bleeding.
⭕️ Fatigue, pallor, dyspnea, tachycardia, and jaundice related to hemolytic anemia.
⭕️ Headache, confusion, visual changes, transient focal symptoms, seizures, or coma.
⭕️ Dark urine caused by hemoglobinuria.
⭕️ Abdominal pain, nausea, vomiting, or diarrhea due to mesenteric ischemia.
⭕️ Chest pain, elevated troponin, arrhythmias, or myocardial ischemia.
⭕️ Mild-to-moderate renal dysfunction; marked renal failure should broaden the differential toward other thrombotic microangiopathies.
Fever may occur, but it is not mandatory. Similarly, major neurologic or renal involvement may be absent at presentation.
✅️ PHYSICAL EXAMINATION AND CLINICAL PEARLS 👂
🔸 Petechiae or non-blanching purpura, often prominent on the lower limbs.
🔸 Pallor, mild jaundice, tachycardia, and signs of tissue hypoperfusion.
🔸 Fluctuating attention, confusion, headache, or subtle cognitive changes.
🔸 No splenomegaly is typically expected in isolated iTTP.
🔸 New chest pain, dyspnea, syncope, or electrocardiographic changes require urgent assessment for cardiac involvement.
🔸 Neurologic symptoms can fluctuate and may disappear between episodes; a normal examination at one moment does not exclude TTP.
🔸 Purpura plus anemia, severe thrombocytopenia, schistocytes, elevated LDH, and normal coagulation studies should raise immediate concern for TTP.
✅️ DIAGNOSIS (2025–2026) 🧩
Step 1 – Recognize thrombotic microangiopathy:
➡️ Complete blood count with severe thrombocytopenia and anemia.
➡️ Peripheral blood smear showing schistocytes.
➡️ Hemolysis profile: elevated LDH, indirect bilirubin, reticulocytosis, low haptoglobin, and usually negative direct antiglobulin test.
➡️ Coagulation tests: PT, aPTT, and fibrinogen are usually not markedly altered, helping distinguish TTP from disseminated intravascular coagulation.
Step 2 – Obtain ADAMTS13 studies urgently:
➡️ ADAMTS13 activity.
➡️ Anti-ADAMTS13 inhibitor and/or anti-ADAMTS13 IgG.
➡️ The sample must be collected before plasma exchange or plasma-containing blood products whenever possible.
Interpretation:
🔹 ADAMTS13 activity
